This presentation contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.
Agenda

Overview | Strategy
Mid-term Growth Prospects
H1 2022 Results | FY 2022 Guidance
Appendix
Our mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.
Sartorius Stedim Biotech at a glance

- **€2.89bn**
  Sales revenue 2021

- **~23%**
  Sales CAGR\(^1\) 2016-2021

- **~35.8%**
  EBITDA margin\(^2\) 2021

- **>25**
  countries, headquartered in Aubagne, France

- **> 11,900**
  Employees 06/2022

---

### Four strong pillars drive above-average growth

- **Pharma market**
  CAGR 4-7%

- **Biopharma market**
  CAGR ~10%

- **Single-use penetration**
  Double-digit growth

- **Market share gains**
  Esp. in North America

---

1 In constant currencies  
2 Excluding extraordinary items
Covering most steps of the biopharmaceutical manufacturing process

- Differentiated by the range and completeness of the portfolio
- Excellent positioning in key single-use technologies
- Internationally recognized supplier enabling innovation in bioprocessing through own R&D and partnerships
Generating revenue throughout the lifecycle of a biopharma drug

- Wide product range of equipment and consumables for all stages (from pre-commercial to large-scale manufacturing); optimal scalability
- Engineering support with excellent application knowhow and understanding of the entire bio-production process
- Production process of each individual drug is subject to validation by health authorities (e.g. FDA, EMA) and part of the drug approval
Integrated services and technologies for all types of biopharmaceuticals

- ~95% of revenue generated with bio/pharma customers
- Antibodies are most relevant; strong position in vaccines as well
- SSB provides solutions for the development and production of all biotechnologically derived drugs and cell derivatives
- These also include new modalities such as cell and gene therapies and viral vectors
The market landscape is dynamic across therapy modalities

**Protein-based therapies**
- mAbs
- Bi-/Multi-specifics
- Bioconjugates | ADCs
- Recombinant proteins and peptides
- Protein-based vaccines

**Viral-based therapies**
- Viral vectors for gene therapy
- Virus and viral vector vaccines
- Oncolytic viruses
- Novel modalities (e.g., mRNA, DNA, Exosomes)

**Advanced therapies**
- Cell therapy (e.g., iPSC, MSC)
- Gene-modified cell therapy (CAR-T)

---

**Unmet needs**

**Efficiency**
**Yields**
**Robust manufacturing**

Share of molecules in R&D pipeline; source: Global Data, March 2021
Attractive market environment offers strong growth opportunities

Growing and aging population
9 billion people by 2050

World population over age 60 in 2050
>2bn

World population over 60 in 2021
~1bn

Biologics are gaining importance
Sales share of biologics in 2026
~37%

Sales share of biologics in 2021
~34%

~10% CAGR biopharma market 2021 - 2026

# Sustainable Profitable Growth

### Key Figures:

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales CAGR</th>
<th>EBITDA Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>~ €477m</td>
<td>+10.3%</td>
</tr>
<tr>
<td>2012</td>
<td>20.9</td>
<td>+10.8%</td>
</tr>
<tr>
<td>2013</td>
<td>21.5</td>
<td>+15.9%</td>
</tr>
<tr>
<td>2014</td>
<td>23.0</td>
<td>+19.4%</td>
</tr>
<tr>
<td>2015</td>
<td>23.5</td>
<td>+20.4%</td>
</tr>
<tr>
<td>2016</td>
<td>26.2</td>
<td>+4.1%</td>
</tr>
<tr>
<td>2017</td>
<td>27.5</td>
<td>+13.7%</td>
</tr>
<tr>
<td>2018</td>
<td>27.3</td>
<td>+18.8%</td>
</tr>
<tr>
<td>2019</td>
<td>28.2</td>
<td>+34.6%</td>
</tr>
<tr>
<td>2020</td>
<td>29.3</td>
<td>+52.6%</td>
</tr>
<tr>
<td>2021</td>
<td>31.7</td>
<td>~ €2.89bn</td>
</tr>
</tbody>
</table>

- **Sales CAGR**: ~+19%
- **EBITDA Margin**: +14.9pp

**Note:**
- Sales growth and CAGR in constant currencies
- Excluding extraordinary items

**Revenue and EBITDA Margin:***

- **EBITDA Margin** increased by 14.9 percentage points.
- **Sales CAGR** showed a steady growth from ~€477m in 2011 to ~€2.89bn in 2021.

---

**Sartorius Stedim Biotech Group**

---

---
Regionalizing our supply chain and manufacturing; increasing our global capacity

**Germany | Göttingen, Guxhagen**
Production capacities increasing

- Separation
- Instruments and systems

**China and South Korea**
Capacities will be created in selected areas

- Separation
- Fluid management
- Cell culture media

**Puerto Rico and USA**
Capacities will be ramped up for selected areas

- Cell culture media
- Fluid management
- Customer interaction
M&A strategy – adding innovation, enhancing focus

**Acquisition criteria**

- Portfolio: Complementary products or technologies
- Market position: Either among the Top 3 or unique selling point
- Integration: Management capacity; cultural fit
- Price: Fair valuation; reach Sartorius’ profitability level in 2-3 years

---

1. Acquired from Danaher
2. Subject to regulatory approval, closing expected before the end of the third quarter of 2022
Recent acquisitions make us an even more relevant partner across the biopharma production workflow

- Expanded portfolio in areas where we used to have a limited offering (e.g., media, purification)
- Focus on innovative technologies especially for cell and gene therapies

**Downstream processing**
Chromatography systems for smaller biomolecules and innovative systems for continuous manufacturing processes

**Cell and gene therapies**
Cell culture media and components for the production of cell and gene therapies and vaccines

- **Novasep chromatography business**
  (February 2022)
- **CellGenix**
  (July 2021)
- **Xell**
  August 2021
- **Albumedix**
  August 2022

→ Tapping growth opportunities in both established as well as emerging areas

1 Subject to regulatory approval, closing expected before the end of the third quarter of 2022
CellGenix – Extending our cell culture media offering

Portfolio

- Critical cell culture components for advanced therapies
- Portfolio includes cytokines and growth factors, cell culture media, supplements and cells

Strategic fit

- Perfect fit with our existing media offering; combined portfolio makes us even more relevant for customers in this fast-growing segment of the biopharma market
- Freiburg to be established as a Group-wide competence center for the development and production of cell culture components

Freiburg, Germany

~70 employees

GMP manufacturing and R&D laboratories

Acquired July 2021

Freiburg, Germany
~70 employees
GMP manufacturing and R&D laboratories

Acquired July 2021

Cytokines and growth factors
Cell culture media
Supplements and cells
Xell – Another building block to establish a strong media business

**Bielefeld, Germany**

- ~35 employees
- Major state-of-the-art capacity expansion recently completed
- Acquired July 2021

**Portfolio**

- Media and feed supplements for cell cultures; focus on viral vectors that are used in gene therapeutics and vaccines
- Analytical services for characterizing, screening, and quantifying media components, as well as for optimizing media composition

**Strategic fit**

- Expanding our current media offering by specialized media and strengthen media analytics capabilities
- Accelerating the expansion of our production network in this fast-growing area

Cell culture media and feed supplements
Acquisition of Novasep’s chromatography division strengthens the downstream offering

Portfolio
- Chromatography systems primarily suited for smaller biomolecules, such as oligonucleotides, peptides, and insulin, as well as innovative systems for continuous manufacturing of biologics
- Since 2018, Novasep and Sartorius Stedim Biotech have also been jointly developing optimized systems for a membrane-based chromatography technology

Strategic fit
- Closing last gaps in our chromatography portfolio; improves access to certain types of customers
- Sartorius is now able to support all purification strategies; equally strong partner in upstream and downstream processing
Acquisition of Albumedix to expand offering for advanced therapies

Nottingham, UK
>100 employees
GMP manufacturing and R&D laboratories
33m revenue expected for 2022, significant double-digit EBITDA margin

Strategic rationale
- Leader in the field of recombinant albumin, a critical component in the manufacture and formulation of innovative biopharmaceuticals
- Strengthens Sartorius’ position as a relevant supplier of chemically defined media and critical ancillary materials
- Complements cell culture media business particularly for advanced therapy

Acquisition terms
- Purchase price of ~£415 in cash for 100% stake
- Transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022

Recombinant albumin
# Competitive portfolio across our relevant end-markets

<table>
<thead>
<tr>
<th>Sartorius</th>
<th>Merck</th>
<th>Millipore</th>
<th>Pall</th>
<th>Danaher</th>
<th>Cytiva¹</th>
<th>Thermo Fisher</th>
<th>Top 3 Players</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filtration</td>
<td><img src="image" alt="Yellow Circle" /></td>
<td><img src="image" alt="Grey Circle" /></td>
<td><img src="image" alt="Grey Circle" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Grey Circle" /></td>
<td>1./2./3. Merck</td>
</tr>
<tr>
<td>Fluid Management</td>
<td><img src="image" alt="Yellow Circle" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td>1. SSB</td>
</tr>
<tr>
<td>Fermentation</td>
<td><img src="image" alt="Yellow Circle" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td>1. SSB</td>
</tr>
<tr>
<td>Purification</td>
<td><img src="image" alt="Yellow Circle" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td>1. Danaher</td>
</tr>
<tr>
<td>Cell Culture Media</td>
<td><img src="image" alt="Yellow Circle" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td><img src="image" alt="Pie Chart" /></td>
<td>1. Thermo Fisher</td>
</tr>
</tbody>
</table>

¹ Formerly GE Biopharma

Pie charts indicate completeness of product offering
Pioneer and leader in the growing single-use technology market

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

- Capex|Opex reduction over entire lifecycle
- Reduced risk of cross-contamination
- Higher flexibility; advantageous for biosimilars

Source: Andrew Sinclair et al., 2008; Sartorius
Single-use allows manufacturers to mitigate investment risks

- Construction of stainless-steel based facilities takes longer and is more complex compared to single-use
- Therefore, investment in stainless-steel facilities has to start in early clinical phase II
- The construction of single-use facilities may start in clinical phase III, reducing investment risks of our clients

<table>
<thead>
<tr>
<th>Clinical Phase</th>
<th>Probability that candidate advances to next stage</th>
<th>Probability of approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I</td>
<td>~ 60%</td>
<td>~ 10%</td>
</tr>
<tr>
<td>Phase II</td>
<td>~ 30%</td>
<td>~ 15%</td>
</tr>
<tr>
<td>Phase III</td>
<td>~ 50%</td>
<td>~ 50%</td>
</tr>
</tbody>
</table>

Data based on: Wong et al. (2018): Estimation of clinical trial success rates and related parameters
More than half of 2021 SSB sales were generated with the Top 50 customers.

Largest customer accounts for approx. 5% of SSB sales revenue.

Limited dependence on individual accounts.
Agenda

Overview | Strategy

Mid-term Growth Prospects

H1 2022 Results | FY 2022 Guidance

Appendix
2025 ambition

- 2025 revenue target does not include any potential pandemic-related sales (vs. ~€500m generated in FY21 and ~€250m expected for FY22)
- The margin target includes expenses for reduction of the company’s CO₂ emission intensity of around 1% of sales

Sartorius Stedim Biotech Group

Sales revenue

€4bn

EBITDA margin

>35%

2025 targets are based on 2020 currency exchange rates; EBITDA excluding extraordinary items
U.S. remains most important market; China with highest growth rates

Biologics market growth forecast

2020

- U.S.: ~119
- Europe: ~46
- China: ~38
- ROW: ~47

~€250bn

CAGR

- U.S.: ~9%
- Europe: ~6%
- China: ~15%

2024

- U.S.: ~167
- Europe: ~58
- China: ~67
- ROW: ~72

~€365bn

Source: Evaluate Pharma, July 2021; Daedal Research, December 2020; Sartorius Stedim Biotech Group
The Chinese market is in the next development phase

Dynamic increase in new biopharma companies

Increasingly focusing on innovative medicines

China’s activity as a percentage of global activity

Innovation 1.0
“fast follow” on validated or clinical targets

Innovation 2.0
Biologics innovators, indication expansion, technology modification

Innovation 3.0
New modalities/New MOAs

Source: BCG, Sartorius
The U.S. and Asia are a focus of the regional growth strategy

**Markets**

- **U.S.**: Highly innovative market, further potential for market share gains
- **Asia**: Strong growth in China, Korea and other countries
- **China**: Developing into an innovative biopharma hub and plays an important role in global biosimilar development and production

**Initiatives**

- Targeted strengthening of sales and service capacities
- Expansion of the regional production network and local value creation

---

**Sales development by region**

Sales share 2021 | CAGR 2011-2021

- **Asia | Pacific**: ~26% | ~22%
- **Europe**: ~41% | ~18%
- **Americas**: ~33% | ~20%
Biosimilars: Strong growth, big opportunities

- Major blockbuster biologics are going off-patent
- Time-to-market is key as only the first providers are most likely profitable
- Several approvals in Asia and Europe; U.S. at the beginning
- For now, relatively small market but with strong growth
- Single-use is the preferred platform for biosimilars

Biosimilars will outperform the biologics market

<table>
<thead>
<tr>
<th>Year</th>
<th>Biosimilars</th>
<th>Other Biologics</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>~14.5</td>
<td>~235.5</td>
</tr>
<tr>
<td>2024</td>
<td>~32.5</td>
<td>~323.5</td>
</tr>
</tbody>
</table>

~+30% CAGR

Growing number of approved biosimilars

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>7</td>
<td>22</td>
<td>20</td>
<td>15</td>
<td>16</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>

Source: Evaluate Pharma, July 2021; BCC Research, 2019; Sartorius
High innovation dynamics in Biopharma

- Development of new drugs and vaccines must be accelerated, e.g. through more automation.
- Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars.
- New tools and methods required e.g. for novel cell and gene therapies.
- Future drug manufacturing is more automated, intensified and scalable.
Analytical technologies to improve process economics and safety

- Bioprocess sensors, analyzers and software
- Collect, monitor and control quality-critical parameters
- Analyze data to obtain a better process understanding
- Use knowledge for process development, optimization and automation
- Allows customers to increase time-to-market, to reduce COGS, to improve process robustness and product quality
- Intention to upgrade Umetrics software suite with advanced analytics technologies such as AI and machine learning
- Data analytics just at the beginning in biomanufacturing with high potential
Agenda

Overview | Strategy
Mid-term Growth Prospects
H1 2022 Results | FY 2022 Guidance
Appendix
# Double-digit increase in sales revenue and earnings

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>H1 2021</th>
<th>H1 2022</th>
<th>▲ in %</th>
<th>▲ in % cc(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue</td>
<td>1,351.9</td>
<td>1,724.3</td>
<td>+27.5</td>
<td>+22.1</td>
</tr>
<tr>
<td>Order intake</td>
<td>1,889.9</td>
<td>1,826.7</td>
<td>-3.3</td>
<td>-7.3</td>
</tr>
<tr>
<td>Underlying EBITDA(^2)</td>
<td>487.4</td>
<td>607.0</td>
<td>24.5</td>
<td></td>
</tr>
<tr>
<td>Underlying EBITDA(^2) margin in %</td>
<td>36.1</td>
<td>35.2</td>
<td>-0.9pp</td>
<td></td>
</tr>
<tr>
<td>Underlying EPS(^3) in €</td>
<td>3.49</td>
<td>4.40</td>
<td>+26.0</td>
<td></td>
</tr>
</tbody>
</table>

- Acquisitions contribute around 2pp to sales growth; sales with coronavirus vaccine customers declining
- OI is normalizing as expected; prior-year figure impacted by pandemic and changed ordering patterns by some customers
- Underlying EBITDA margin influenced by higher costs (as planned) and FX headwinds

---

1 Constant currencies  
2 Underlying = excluding extraordinary items  
3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
High double-digit sales growth in all regions led by the Americas

- Dynamic increase in the Americas
- EMEA with substantial growth against high comparables
- Strong growth in Asia|Pacific; partial lockdowns in China with overall minor impact

Acc. to customers’ location; growth in constant currencies
### Sartorius Stedim Biotech Group

#### in millions of € unless otherwise specified

<table>
<thead>
<tr>
<th></th>
<th>H1 2021</th>
<th>H1 2022</th>
<th>▲ in %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underlying EBITDA</td>
<td>487.4</td>
<td>607.0</td>
<td>+24.5</td>
</tr>
<tr>
<td>Extraordinary items</td>
<td>-7.0</td>
<td>-5.0</td>
<td>+28.9</td>
</tr>
<tr>
<td>Financial result</td>
<td>-26.5</td>
<td>102.4</td>
<td>n.m.</td>
</tr>
<tr>
<td>Underlying net profit$^{1,2}$</td>
<td>321.6</td>
<td>405.2</td>
<td>+26.0</td>
</tr>
<tr>
<td>Reported net profit$^{2}$</td>
<td>274.2</td>
<td>484.9</td>
<td>+76.8</td>
</tr>
<tr>
<td>Operating cash flow</td>
<td>368.1</td>
<td>247.3</td>
<td>-32.8</td>
</tr>
<tr>
<td>Investing cash flow$^{3}$</td>
<td>-114.5</td>
<td>-224.9</td>
<td>-96.4</td>
</tr>
<tr>
<td>CAPEX ratio (in %)</td>
<td>8.4</td>
<td>10.4</td>
<td>+2.0pp</td>
</tr>
</tbody>
</table>

H1 2021 figures restated due to final PPA for the acquisition of BIA Separations. 1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and a normalized tax rate. 2 After non-controlling interest. 3 Net cash flow from investing activities and acquisitions.

---

**Strong cash flow influenced by buildup of inventories**

- Cash flow influenced by higher inventories to support supply security.
- Financial result mainly driven by valuation effect of earn-out liability regarding BIA Separations.
- Investing cash flow reflects substantial CAPEX program and M&A.
Robust financial indicators; low dynamic debt ratio

### Key Financial Indicators

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>Dec. 31, 2021</th>
<th>June 30, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity ratio in %</td>
<td>43.9</td>
<td>48.6</td>
</tr>
<tr>
<td>Net debt in millions of €</td>
<td>401.9</td>
<td>576.1</td>
</tr>
<tr>
<td>Net debt</td>
<td>underlying EBITDA(^1)</td>
<td>0.4</td>
</tr>
</tbody>
</table>

\(^1\) Includes underlying pro forma EBITDA of acquisitions completed in 2021 and 2022

### Net Debt and Net Debt to Underlying EBITDA

![Graph showing net debt and net debt to underlying EBITDA over time from Q1 to Q4, 2014 to 2022.](image-url)

- Net debt in millions of € (lhs)
- Net debt to underlying EBITDA (rhs)
Guidance 2022 confirmed: Double-digit sales growth, sustained high profitability; uncertainties remain high

<table>
<thead>
<tr>
<th>Guidance 2022¹</th>
<th>Sales revenue growth</th>
<th>Underlying EBITDA margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius Stedim Biotech Group</td>
<td>~15% - 19%</td>
<td>&gt;35%</td>
</tr>
<tr>
<td>thereof from acquisitions</td>
<td>~2pp</td>
<td></td>
</tr>
</tbody>
</table>

- Corona-related business now expected at around €250 million (previously: €500 million as in 2021)
- Margin target includes expenses for reduction of CO₂ emission intensity of approx. 0.5% of sales
- CAPEX ratio expected at around 14.5%
- Net debt to underlying EBITDA anticipated at around 0.2

¹ In constant currencies
Agenda

Overview | Strategy
Mid-term Growth Prospects
H1 2022 Results | FY 2022 Guidance

Appendix
To Sartorius Stedim Biotech, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

Please click below for further financial information:

- Half-Year Report H1 2022
- Earnings Release Q1 2022
- Annual Report 2021
- Earnings Release 9M 2021
Sartorius Stedim Biotech shares – an attractive investment

- Biopharma market fueled by long-term growth drivers
- Leading market positions in key technologies and high brand awareness
- Global presence with strong base in growth regions
- High entry barriers, low price-sensitivity and consolidated competitive landscape
- Diversified revenue base and high share of recurring revenues provide low volatility
- Proven growth track record: Sales CAGR\(^1\) of ~23% over the last five years

\(^1\) In constant currencies
Share price performance

<table>
<thead>
<tr>
<th>ISIN</th>
<th>FR0013154002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticker</td>
<td>DIM</td>
</tr>
<tr>
<td>Number of share</td>
<td>92,180,190</td>
</tr>
<tr>
<td>Indices</td>
<td>SBF 120</td>
</tr>
<tr>
<td>Market cap.</td>
<td>€33.9bn (as of July 21, 2022)</td>
</tr>
</tbody>
</table>
A sampling of the product portfolio

Filtration

Purification

Fermentation

Fluid management
Contacts and Financial calendar

- **September 6, 2022**
  ODDO Sector Conference | Frankfurt

- **September 12-13, 2022**
  Morgan Stanley Global HC Conference | New York

- **September 14, 2022**
  BofAML Global HC Conference | London

- **September 20-21, 2022**
  Berenberg & Goldman Sachs German Corporate Conference | Munich

- **September 22, 2022**
  Baader Investment Conference | Munich

- **September 27, 2022**
  Citi’s European HC Bus Tour | Frankfurt

- **October 19, 2022**
  Publication nine-months 2022 Results | Göttingen

Petra Kirchhoff  
Head of Corporate Communications & IR  
+49.551.308.1686  
petra.kirchhoff@sartorius.com

Petra Müller  
Head of Investor Relations  
+49.551.308.6035  
petra.mueller2@sartorius.com

Mirko Koch  
Manager Investor Relations  
+49.551.308.2402  
mirko.koch@sartorius.com

Sartorius Corporate Administration GmbH  
Otto-Brenner-Straße 20  
37079 Göttingen, Germany
Scan or click here to visit our IR website.